ClinicalTrials.gov
ClinicalTrials.gov Menu

Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (SPORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00584363
Recruitment Status : Completed
First Posted : January 2, 2008
Last Update Posted : October 5, 2017
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Charles Mel Wilcox, MD, University of Alabama at Birmingham

Brief Summary:
The purpose of the study is to collect pancreatic tissue, blood and urine from adults to study pancreatic abnormalities.

Condition or disease
Pancreatic Cancer

Detailed Description:
The aim of the study is to standardize, collect and share pancreatic cancer related information, to be used for research purposes only by researchers from different participating institutions/centers.

Study Type : Observational
Actual Enrollment : 731 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)
Study Start Date : June 2004
Actual Primary Completion Date : September 2017
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. To diagnose Pancreatic Cancer [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Preventing patient form being misdiagnosed [ Time Frame: 5 years ]

Biospecimen Retention:   Samples With DNA
Specimens are frozen and stored


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults 19 years of age or older, pancreatic cancer patients at the University of Alabam at Birmingham.
Criteria

Inclusion Criteria:

  • Person over 19 years of age, patient with a tissue-proven diagnosis of pancreatic cancer at the University of Alabama at Birmingham (UAB) University Hospital during the period, and cognitive ability to provide informed consent

Exclusion Criteria:

  • Person not 19 or older and have not had a tissue-proven diagnosis of pancreatic cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00584363


Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
National Cancer Institute (NCI)
Investigators
Principal Investigator: Charles M Wilcox, MD University of Alabama at Birmingham

Responsible Party: Charles Mel Wilcox, MD, Principal Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00584363     History of Changes
Other Study ID Numbers: F040514008
2P50CA101955 ( U.S. NIH Grant/Contract )
First Posted: January 2, 2008    Key Record Dates
Last Update Posted: October 5, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Gastrointestinal Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gastrointestinal Diseases